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Anaphylaxis is characterized by life-threatening upper
airway obstruction, bronchospasm and/or hypoten-
sion. This once highly fatal IgE-mediated event has
entered a new era with extremely low mortality as a
result of early recognition and effective treatment.1
However, this is not the case in patients who have
anaphylaxis during anesthesia because of deep sedation,
interaction of multiple medications, and complex car-
diac and respiratory physiology during ventilation,
which hamper the diagnosis. The anaphylactic reac-
tion during anesthesia carries a mortality of 3–6% and
results in 2% of patients with significant residual brain
damage.2 However, a study has reported that none of
42 anesthesiologists tested on a simulator made the
correct diagnosis and treatment during the first 10 min-
utes of anaphylaxis,3 which further emphasizes the
importance of early recognition of this uncommon but
deadly reaction. Kuo et al rapidly identified a series of
anesthetized patients with elevation of airway pressure
as having anaphylaxis-related bronchospasm, after ex-
cluding the other possibilities, such as problems with
the breathing circuit, anesthetic machines and the
patient’s condition.4
Although the most common culprit medications
for anaphylaxis in sedated patients are neuromuscular
blocking agents (69.2%) followed by latex (12.1%),5 a
new brand of cephalexin (Roles; Gentle Pharmaceuti-
cal Corporation Kashin Medicines Co., Ltd., Yunlin,
Taiwan), a first-generation cephalosporin, has been in-
criminated based on time sequence and statistical analy-
ses. Although penicillins are notorious for immediate
reactions, events caused by cephalosporins have in-
creased with their use as the first drug of choice for a
wide variety of infections and prophylaxis in many sur-
gical procedures. Cephalosporins are semi-synthetic
antimicrobial agents that are derived from Cephalospo-
rium acremonium and have a β-lactam ring attached
to a 6-member dihydrothiazine ring. Substitution at
side chains R1 in the C7 and R2 in the C3 position
allows for variation in the antimicrobial spectrum and
pharmacokinetic properties. Cephalosporin-induced
anaphylaxis is an immediate reaction mediated by IgE
antibodies, which can react with different portions of
cephalosporins, ranging from a small region to a full
side chain, a side chain conjugated with a protein, or
the whole cephalosporin molecule.6 Uncertainty about
the antigenic determinant of cephalosporins has hin-
dered studies of recognition of IgE-specific antibodies
and development of in vitro and in vivo diagnostic tests
to preclude the patients at risk. A recent study has
indicated that the R1 acyl side chain and the β-lactam
fragment that are linked to the carrier protein are one
of the IgE-binding determinants, because the R2 side
chain can be lost during metabolism of cephalosporins.7
In that same study, use of cefazolin, which has differ-
ent R1 and R2 side chains from cephalexin, was not
associated with anaphylaxis, which indicated that the
cephalosporin nucleus should not be blamed. No ad-
verse events have been reported in our institution after
use of cephradine, another common prophylactic anti-
biotic with the same R1 side chain as cephalexin. Sub-
sequent administration of another brand of cephalexin
did not result in such a high incidence of broncho-
spasm. The results indicated that the R1 side chain
might not be responsible for the bronchospasms. Fur-
thermore, the low incidence of anaphylactic reactions
to cephalosporins (0.0001–0.1%)6 makes the occur-
rence of cephalosporin-induced anaphylaxis in such
large numbers of patients and within such a short pe-
riod less possible. Furthermore, most of the patients had
no history of allergy to β-lactam antibiotics. Broncho-
spasm might not be the result of allergy to cephalexin
but to other components in the drug formulation be-
cause excipient- or additive-related bronchospasm has
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been reported in the literature.8 Another consideration
is the rapidity of administration of Roles. Red man
syndrome, caused by a degranulation effect of van-
comycin on mast cells and basophils has also been
reported in patients receiving ciprofloxacin, ampho-
tericin B, rifampicin, and teicoplanin.9 The histamine
release was highly associated with rapid infusion of the
causative agent. However, further studies are needed
to elucidate the relationship between Roles and this
phenomenon.
Available laboratory tests of mast cell and basophil
activation products in clinical practice include tests for
histamine and total tryptase. The utility of β-tryptase,
mast cell carboxypeptidase A3, chymase, platelet-
activating factor and other cytokines is under investi-
gation. However, their use is limited in the diagnosis of
acute anaphylaxis, with suboptimal specificity and sen-
sitivity. Of great concern are those patients who have
a history of previous penicillin allergy but who will
receive cephalosporin for prophylaxis during surgery.
The possible severe sequelae preclude in vivo testing
such as skin and challenge tests. As mentioned above,
lack of knowledge of the exact chemical structure of
cephalosporin allergenic determinants has hampered
the development of in vitro diagnostic testing to antici-
pate anaphylaxis. Thorough history taking and physician
alertness are essential for early diagnosis and treatment
of anaphylaxis. Termination of the possible offending
cephalosporin is the right way to settle the problem.
However, if there is genuine cephalosporin anaphy-
laxis in a patient, avoidance of further administration of
any β-lactam antibiotics might be warranted, because
it is hard to identify the exact determinant that causes
anaphylaxis. When it is still necessary to prescribe 
β-lactam antibiotics, one should at least avoid those
with a similar R1 side chain. For example, one should
avoid the use of (to name a few) cephradine, cefaclor
and even ampicillin6 in patients who have an anaphy-
lactic reaction to cephalexin.
References
1. Simons FE. Anaphylaxis: recent advances in assessment and
treatment. J Allergy Clin Immunol 2009;124:625–36.
2. Fisher MM, Baldo BA. The incidence and clinical features of
anaphylactic reactions during anesthesia in Australia. Ann Fr
Anesth Reanim 1993;12:97–104.
3. Jacobsen J, Lindekaer AL, Ostergaard HT, Nielsen K, Ostergaard
D, Laub M, Jensen PF, et al. Management of anaphylactic
shock evaluated using a full-scale anaesthesia simulator. Acta
Anaesthesiol Scand 2001;45:315–9.
4. Kuo YM, Ting CK, Wang YC, Chang WK, Wu HL, Chan KH,
Chen PT. Prophylactic antibiotic administration induced bron-
chospasm as increased airway pressure during general anesthe-
sia. J Chin Med Assoc 2009;73: 72–7.
5. Laxenaire MC, Mertes PM. Anaphylaxis during anaesthesia.
Results of a two-year survey in France. Br J Anaesth 2001;
87:549–58.
6. Moreno E, Macias E, Davila I, Laffond E, Ruiz A, Lorente F.
Hypersensitivity reactions to cephalosporins. Expert Opin
Drug Saf 2008;7:295–304.
7. Perez-Inestrosa E, Suau R, Montanez MI, Rodriguez R, Mayorga
C, Torres MJ, Blanca M. Cephalosporin chemical reactivity
and its immunological implications. Curr Opin Allergy Clin
Immunol 2005;5:323–30.
8. Leuppi JD, Schnyder P, Hartmann K, Reinhart WH, Kuhn M.
Drug-induced bronchospasm: analysis of 187 spontaneously
reported cases. Respiration 2001;68:345–51.
9. Sivagnanam S, Deleu D. Red man syndrome. Crit Care 2003;
7:119–20.
J Chin Med Assoc • April 2010 • Vol 73 • No 4182
T.L. Chen
